Michael C. Milone

faculty photo
Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Staff Physician, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
Associate Vice Chair for Profession Development and Academic Affairs, Department of Pathology and Laboratory Medicine, Perelman School of Medicine,
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
3400 Spruce Street 7103 Founders Pavilion
Philadelphia, PA 19104
Office: 215-662-6575
Fax: 215-662-7529
Education:
B.S (Chemical Biology)
Stevens Institute of Technology, 1993.
M.D. (Medical Doctor)
UMDNJ- New Jersey Medical School, 1999.
Ph.D (Experimental Pathology/ Immunology)
UMDNJ - Graduate School of Biomedical Sciences, 1999.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease.

Active research projects in my laboratory include:

1) Developing chimeric antigen receptors (CARs) and other engineering approaches for enhancing the function and improved safety of adoptive T cell therapy.

2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.

3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.

Description of Clinical Expertise

Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis

Selected Publications

Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG.: Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Rep Med 4: 101336, Dec 2023.

Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton RD, Pajarillo R, Patel V, White G, Ballard H, Weber E, Napier EB, Chong ER, Fraietta JA, Garfall A, Porter DL, Milone MC, O'Connor RS, Schuster SJ, Ruella M.: Bendamustine Lymphodepletion Before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines. Blood Adv Dec 2023.

Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, Greene MI.: F77 antigen is a promising target for adoptive T cell therapy of prostate cancer. Biochem Biophys Res Commun 680: 51-60, Nov 2023.

Thakrar AP, Faude S, Perrone J, Milone MC, Lowenstein M, Snider CK, Spadaro A, Delgado MK, Nelson LS, Kilaru AS.: Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department. J Addict Med Mar 2023.

Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA.: Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov 4: 118-133, Mar 2023.

Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS.: Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol Jan 2023.

Glisovic-Aplenc, T., Diorio, C., Chukinas, J. A., Veliz, K., Shestova, O., Shen, F., Nunez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., June, C. H., Teachey, D. T., Tasian, S. K., Aplenc, R., Gill, S.: CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv 7(16): 4418-4430, 2023.

Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV.: Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discov. Aug 2022 Notes: OF1-OF12. doi: 10.1158/2643-3230.BCD-22-0018. Online ahead of Print.

Ellis, G. I., Coker, K. E., Winn, D. W., Deng, M. Z., Shukla, D., Bhoj, V., Milone, M. C., Wang, W., Liu, C., Naji, A., Duran-Struuck, R., Riley, J. L.: Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque. Cell Rep Med 3(5): 100614, 2022.

Ellis, G. I., Deng, M. Z., Winn, D. W., Coker, K. E., Shukla, D., Bhoj, V., Milone, M. C., Duran-Struuck, R., Riley, J. L.: Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation. STAR Protoc 3(4): 101784, 2022.

back to top
Last updated: 01/16/2024
The Trustees of the University of Pennsylvania